Vaccine Conjugates Market Research Report Information By Type (Monovalent, Multivalent), Disease Indication (Pneumococcal, Influenza, Meningococcal), Pathogen Type (Bacterial, Viral, Combination), Patient Stage (Pediatrics, Adult), End-User-Forecast to 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Vaccine Conjugates Market, by Type

6.1 Introduction

6.2 Monovalent Conjugate Vaccines

6.3 Multivalent Conjugate Vaccines

Chapter 7 Global Vaccine Conjugates Market, by Disease Indication

7.1 Introduction

7.2 Pneumococcal

7.3 Influenza

7.4 DTP

7.5 Meningococcal

7.6 Others

Chapter 8 Global Vaccine Conjugates Market, by Pathogen Type

8.1 Introduction

8.2 Bacterial Conjugate Vaccine

8.3 Viral Conjugate Vaccine

8.4 Combination (Viral and Bacterial)

Chapter 9 Global Vaccine Conjugates Market, by Patient Stage

9.1 Introduction

9.2 Pediatrics Conjugate Vaccine

9.3 Adults Conjugate Vaccine

Chapter 10 Global Vaccine Conjugates Market, by End-User

10.1 Introduction

10.2 Research Institute

10.3 Academic Institute

10.4 Pharmaceutical Industries

10.5 Others

Chapter 11. Global Vaccine Conjugates Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 US

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 UK

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia-Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 South Korea

11.4.6 Rest of Asia-Pacific

11.5 Middle East & Africa

11.5.1 Middle East

11.5.2 Africa

Chapter 12. Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

Chapter 13. Company Profiles

13.1 GlaxoSmithKline, plc.

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials Overview

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Merck KGaA

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Neuron Biotech

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Novartis AG

13.4.1 Company Overview

13.4.2 Technology/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Pfizer, Inc.

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Sanofi Pasteur

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Serum Institute of India

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financial Overview

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Biological E

13.8.1 Overview

13.8.2 Product/ Technology Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 CSL Limited

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Bharat Biotech

13.10.1 Overview

13.10.2 Product Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Astellas Pharma

13.11.1 Overview

13.11.2 Product Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

13.12 AstraZeneca

13.12.1 Overview

13.12.2 Product Overview

13.12.3 Financials

13.12.4 Key Developments

13.12.5 SWOT Analysis

13.13 Mitsubishi Tanabe Pharma

13.13.1 Overview

13.13.2 Product Overview

13.13.3 Financials

13.13.4 Key Developments

13.13.5 SWOT Analysis

13.14 Bavarian Nordic

13.14.1 Overview

13.14.2 Product Overview

13.14.3 Financials

13.14.4 Key Developments

13.14.5 SWOT Analysis

13.15 Daiichi Sankyo Company, Limited

13.15.1 Overview

13.15.2 Product Overview

13.15.3 Financials

13.15.4 Key Developments

13.15.5 SWOT Analysis

13.16 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

Chapter 15 Appendix

LIST OF TABLES

Table 1 Global Vaccine Conjugates Market Synopsis, 2018–2027

Table 2 Global Vaccine Conjugates Market Estimates and Forecast, 2018–2027, (USD Million)

Table 3 Global vaccine conjugates market, by Region, 2018–2027, (USD Million)

Table 4 Global vaccine conjugates market, by Product, 2018–2027, (USD Million)

Table 5 Global vaccine conjugates market, by Type, 2018–2027, (USD Million)

Table 6 Global vaccine conjugates market, by Disease Indication, 2018–2027, (USD Million)

Table 7 Global vaccine conjugates market, by Pathogen Type, 2018–2027, (USD Million)

Table 8 Global vaccine conjugates market, by Patient Type, 2018–2027, (USD Million)

Table 9 North America Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 10 North America Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 11 North America Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 12 North America Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 13 North America Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 14 North America Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 15 US Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 16 US Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 17 US Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 18 US Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 19 US Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 20 US Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 21 Canada Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 23 Canada Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 24 Canada Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 25 Canada Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 26 Canada Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 27 Canada Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 28 South America Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 29 South America Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 30 South America Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 31 South America Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 32 South America Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 33 South America Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 34 Europe Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 35 Europe Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 36 Europe Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 37 Europe Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 38 Europe Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 39 Europe Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 40 Western Europe Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 41 Western Europe Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 42 Western Europe Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 43 Western Europe Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 44 Western Europe Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 45 Western Europe Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 46 Eastern Europe Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 47 Eastern Europe Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 48 Eastern Europe Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 49 Eastern Europe Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 50 Eastern Europe Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 51 Eastern Europe Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 52 Asia-Pacific Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 53 Asia-Pacific Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 54 Asia-Pacific Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 55 Asia-Pacific Vaccine conjugates Market, by Pathogen Type, 2018–2027, (USD Million)

Table 56 Asia-Pacific Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

Table 57 Asia-Pacific Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 58 Middle East & Africa Vaccine conjugates Market, by Product, 2018–2027, (USD Million)

Table 59 Middle East & Africa Vaccine conjugates Market, by Type, 2018–2027, (USD Million)

Table 60 Middle East & Africa Vaccine conjugates Market, by Disease Indication, 2018–2027, (USD Million)

Table 61 Middle East & Africa Vaccine conjugates Market, by Pathogen Type 2018–2027, (USD Million)

Table 62 Middle East & Africa Vaccine conjugates Market, by Patient Type, 2018–2027, (USD Million)

Table 63 Middle East & Africa Vaccine conjugates Market, by End-User, 2018–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global vaccine conjugates market

Figure 3 Segmentation Market Dynamics for Global vaccine conjugates market

Figure 4 Global Vaccine Conjugates Market Share, by Product 2017

Figure 5 Global Vaccine Conjugates Market Share, by Type 2017

Figure 6 Global Vaccine Conjugates Market Share, by Disease Indication 2017

Figure 7 Global Vaccine Conjugates Market Share, by Pathogen Type 2017

Figure 8 Global Vaccine Conjugates Market Share, by Patient Type 2017

Figure 9 Global Vaccine Conjugates Market Share, by End-User 2017

Figure 10 Global Vaccine Conjugates Market Share, by Region, 2017

Figure 11 North America Vaccine Conjugates Market Share, by Country, 2017

Figure 12 Europe Vaccine Conjugates Market Share, by Country, 2017

Figure 13 Asia-Pacific Vaccine Conjugates Market Share, by Country, 2017

Figure 14 Middle East & Africa Vaccine Conjugates Market Share, by Country, 2017

Figure 15 Global vaccine conjugates market: Company Share Analysis, 2017 (%)

Figure 16 GlaxoSmithKline, plc.: Key Financials

Figure 17 GlaxoSmithKline, plc.: Segmental Revenue

Figure 18 GlaxoSmithKline, plc.: Geographical Revenue

Figure 19 Merck KGaA: Key Financials

Figure 20 Merck KGaA: Segmental Revenue

Figure 21 Merck KGaA: Geographical Revenue

Figure 22 Astellas Pharma: Key Financials

Figure 23 Astellas Pharma: Segmental Revenue

Figure 24 Astellas Pharma: Geographical Revenue

Figure 25 AstraZeneca: Key Financials

Figure 26 AstraZeneca: Segmental Revenue

Figure 27 AstraZeneca: Geographical Revenue

Figure 28 Pfizer, Inc.: Key Financials

Figure 29 Pfizer, Inc..: Segmental Revenue

Figure 30 Pfizer, Inc.: Geographical Revenue

Figure 31 Sanofi Pasteur: Key Financials

Figure 32 Sanofi Pasteur: Segmental Revenue

Figure 33 Sanofi Pasteur: Geographical Revenue

Figure 34 Biological E: Key Financials

Figure 35 Biological E: Segmental Revenue

Figure 36 Biological E: Geographical Revenue

Figure 37 AstraZeneca: Key Financials

Figure 38 AstraZeneca: Segmental Revenue

Figure 39 AstraZeneca: Geographical Revenue